Tumor microenvironment-based high-throughput antibody identification.
Area of focus: Therapeutics, Cancer
Commencement date: March, 2016
Location: JLABS @ TMC
Despite universal agreement that new targets and therapeutic candidates are needed, most industry efforts are focused on the same set of known targets. Also, developing a new drug from a new or existing target typically takes many years prior to clinical evaluation. In addition, the area of tumor/tumor microenvironment interactions has emerged as a promising area for exploration, but industry efforts have only recently been launched in this area, and no high-throughput strategies have been developed to address this critical feature of tumor biology.
Based on novel insights into the tumor microenvironment, and without advance designation or even knowledge of cellular targets, Resonant’s platform produces anti-tumor monoclonal antibodies to novel targets from any solid tumor with unprecedented speed. This technology has led to a rapidly expanding pipeline of candidates with potent, direct anti-tumor activity as well as tumor cell selective internalizing activity (ADC vectors), initially in breast, ovarian and lung cancers. Novel tumor antigen targets and binding agents are expected to have unique disease modifying activity as naked mAbs, ADCs, and as components of engineered cell therapies.
In one way or another, cancer impacts all of our lives, yet many cancers still lack therapeutic options that provide hope for a cure. Our frustration with the status quo led to the development of a top-down approach that identifies novel targets and simultaneously provides high affinity functionally active monoclonal antibodies suitable for development. These steps are achieved in a fraction of the time required to prosecute typical drug discovery programs. Resonant’s founders have worked for decades on target and drug discovery, deep data analysis and on seminal studies that have led to our current understanding of the tumor microenvironment. We are dedicated to the discovery of novel therapies for cancer.
Meet the Team:
John K. Westwick, Ph.D.
Stephen J. Weiss, M.D. – Founder and CSO